Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LPL | P06858 | 2/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252186 | 0.87 | TSHR (0.69) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL19487141 | 0.85 | TSHR (0.57) | TSHRTRPV1SMN1; SMN2LPLLIPG | |
| SCHEMBL433769 | 0.83 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL101621 | 0.81 | KMT2A (0.59) | TRPV1LPLLIPGALDH1A1 | |
| SCHEMBL3598006 | 0.79 | TSHR (0.61) | TSHRTRPV1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3598004 | 0.79 | TSHR (0.61) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL1694501 | 0.79 | TRPV1 (0.61) | TSHRTRPV1SMN1; SMN2LPLLIPG | |
| SCHEMBL10117993 | 0.79 | TSHR (0.61) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3006709 | 0.78 | TSHR (0.59) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL2721206 | 0.78 | ALDH1A1 (0.65) | TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, CFH | TSHR 1723/4885TRPV1 3621/4885SMN1; SMN2 2371/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | TSHR 1723/4885TRPV1 3621/4885SMN1; SMN2 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.